When traditional therapies fail, biologics, notably IL-1 blockers such as anakinra or rilonacept, are considered, particularly in corticosteroid-dependent cases [1,8]. IL-1 plays a central role in the pathophysiology of pericarditis by promoting inflammation and immune system activation, which contributes to symptom persistence and recurrence. This evidence concerns the gene IL1B and pericarditis.